Epizyme (EPZM) Highlighted on Sector Deal
Tweet
Share
E-mailEpizyme (NASDAQ: EPZM) highlighted as a comp for MyoKardia (NASDAQ: MYOK), which was acquired today, at Citi. Sees EPZM worth $45-$55 in a deal.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blue Owl Credit Income Corp caps Q2 tender offer at 5% of shares
- Barclays Downgrades Dana Holding (DAN) to Equalweight
- Exelixis (EXEL) PT Raised to $52 at UBS on Upcoming Catalysts
Create E-mail Alert Related Categories
Analyst Comments, Rumors, Trader TalkRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
